# Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

> **NCT00329082** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 25 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** LY2062430
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00329082
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-05
- **Primary completion:** 2008-05
- **Final completion:** 2008-05
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2009-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329082, "Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00329082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*